363 related articles for article (PubMed ID: 21411714)
41. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
42. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
43. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
44. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.
Kievit FM; Wang FY; Fang C; Mok H; Wang K; Silber JR; Ellenbogen RG; Zhang M
J Control Release; 2011 May; 152(1):76-83. PubMed ID: 21277920
[TBL] [Abstract][Full Text] [Related]
45. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
46. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
[TBL] [Abstract][Full Text] [Related]
47. Hexane fraction of adlay (Coix lachryma-jobi L.) testa ethanolic extract inhibits human uterine sarcoma cancer cells growth and chemosensitizes human uterine sarcoma cells to doxorubicin.
Chang CC; Huang LH; Chiang W; Hsia SM
Phytomedicine; 2018 Aug; 47():69-80. PubMed ID: 30166110
[TBL] [Abstract][Full Text] [Related]
48. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
49. Co-responsive smart cyclodextrin-gated mesoporous silica nanoparticles with ligand-receptor engagement for anti-cancer treatment.
Wu Y; Xu Z; Sun W; Yang Y; Jin H; Qiu L; Chen J; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109831. PubMed ID: 31349481
[TBL] [Abstract][Full Text] [Related]
50. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.
Sharma AK; Zhang L; Li S; Kelly DL; Alakhov VY; Batrakova EV; Kabanov AV
J Control Release; 2008 Nov; 131(3):220-7. PubMed ID: 18722489
[TBL] [Abstract][Full Text] [Related]
51. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
52. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
53. A multifunctional nano-delivery system enhances the chemo-
Zhao R; Ning X; Wang M; Yu A; Wang Y
J Mater Chem B; 2021 Nov; 9(44):9174-9182. PubMed ID: 34698329
[TBL] [Abstract][Full Text] [Related]
54. A self-assembled pH/enzyme dual-responsive prodrug with PEG deshielding for multidrug-resistant tumor therapy.
Ni R; Zhu J; Xu Z; Chen Y
J Mater Chem B; 2020 Feb; 8(6):1290-1301. PubMed ID: 31967176
[TBL] [Abstract][Full Text] [Related]
55. Cancer cell membrane-cloaked mesoporous silica nanoparticles with a pH-sensitive gatekeeper for cancer treatment.
Liu CM; Chen GB; Chen HH; Zhang JB; Li HZ; Sheng MX; Weng WB; Guo SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():477-486. PubMed ID: 30572156
[TBL] [Abstract][Full Text] [Related]
56. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.
Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE
ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437
[TBL] [Abstract][Full Text] [Related]
57. Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.
Ai S; Jia T; Ai W; Duan J; Liu Y; Chen J; Liu X; Yang F; Tian Y; Huang Z
Br J Pharmacol; 2013 Apr; 168(7):1719-35. PubMed ID: 23146125
[TBL] [Abstract][Full Text] [Related]
58. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
59. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
60. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
Dong X; Mattingly CA; Tseng MT; Cho MJ; Liu Y; Adams VR; Mumper RJ
Cancer Res; 2009 May; 69(9):3918-26. PubMed ID: 19383919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
